Vir Biotechnology. has been granted a patent for antibodies that target the antigenic loop region of hepatitis B surface antigen, effectively neutralizing hepatitis B and delta viruses. The patent includes specific amino acid sequences for these antibodies, which may be used in diagnosis, prevention, and treatment of hepatitis B and D. GlobalData’s report on Vir Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Vir Biotechnology, Peptide pharmacophores was a key innovation area identified from patents. Vir Biotechnology's grant share as of June 2024 was 21%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies for neutralizing hepatitis b and d viruses
The granted patent US12037381B2 outlines a series of claims related to isolated antibodies and their antigen-binding fragments, specifically targeting hepatitis B and hepatitis D infections. The primary claim details antibodies that include specific amino acid sequences for complementarity-determining regions (CDRs) from both heavy and light chains, identified by various SEQ ID numbers. The patent also encompasses antibodies with a heavy chain variable domain (VH) and a light chain variable domain (VL) that exhibit at least 95% identity to specified sequences. Additional claims describe the antibodies as potentially human, including various forms such as purified antibodies, single-chain antibodies, and fragments like Fab and scFv. Furthermore, the patent covers nucleic acid molecules encoding these antibodies, vectors for expression, and pharmaceutical compositions that combine the antibodies with acceptable excipients.
In addition to the structural claims, the patent presents methods for treating hepatitis B and D infections by administering the described antibodies or fragments to subjects in need. The treatment methods specify conditions under which the antibodies may be administered, including scenarios involving polymerase inhibitors, interferons, or checkpoint inhibitors. The claims also address specific patient populations, such as those with chronic hepatitis B infections, newborns, individuals undergoing hemodialysis, and patients who have received liver transplants. Overall, the patent provides a comprehensive framework for the development and application of these antibodies in therapeutic contexts related to hepatitis infections.
To know more about GlobalData’s detailed insights on Vir Biotechnology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
